LEADER 01000caa a22002652c 4500
001 NLM305792113
003 DE-627
005 20250226152602.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2020.108349  |2 doi 
028 5 2 |a pubmed25n1019.xml 
035 |a (DE-627)NLM305792113 
035 |a (NLM)31982644 
035 |a (PII)S1521-6616(19)30526-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Pisetsky, David S  |e verfasserin  |4 aut 
245 1 4 |a The binding of SLE autoantibodies to mitochondria 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 19.10.2020 
500 |a Date Revised 03.10.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Published by Elsevier Inc. 
520 |a Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes. Because these complexes contain mitochondrial components, we assessed the presence of antibodies to whole mitochondria (wMITO) using an ELISA in which mitochondria from mouse liver are bound to microtiter plates pre-coated with poly-l-lysine. Studies with this ELISA demonstrated that SLE plasmas contain abundant anti-wMITO activity. While digestion with DNase 1 did not affect anti-wMITO activity, adsorption of plasma on DNA affinity columns could reduce binding activity. Assay for anti-mitochondrial antibodies (AMA) by immunofluorescence and an ELISA with the M2 antigen (2-oxo-acid dehydrogenase protein complex) showed a low frequency of positivity, indicating that AMA and anti-wMITO are distinct specificities. In the study of 204 patients with SLE, the levels of anti-wMITO were higher in active SLE and correlated with levels of anti-DNA. These findings suggest that anti-wMITO can form immune complexes with mitochondria which may drive pathogenesis 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Research Support, U.S. Gov't, Non-P.H.S. 
650 4 |a Anti-DNA 
650 4 |a Anti-mitochondrial antibodies 
650 4 |a ELISA 
650 4 |a Immune complexes 
650 4 |a Microparticles 
650 4 |a Mitochondria 
650 4 |a Primary biliary cholangitis 
650 4 |a Systemic lupus erythematosus 
650 7 |a Antibodies, Antinuclear  |2 NLM 
650 7 |a Antigen-Antibody Complex  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Autoantigens  |2 NLM 
650 7 |a Mitochondrial Proteins  |2 NLM 
650 7 |a Polylysine  |2 NLM 
650 7 |a 25104-18-1  |2 NLM 
650 7 |a DNA  |2 NLM 
650 7 |a 9007-49-2  |2 NLM 
650 7 |a Deoxyribonuclease I  |2 NLM 
650 7 |a EC 3.1.21.1  |2 NLM 
700 1 |a Spencer, Diane M  |e verfasserin  |4 aut 
700 1 |a Mobarrez, Fariborz  |e verfasserin  |4 aut 
700 1 |a Fuzzi, Enrico  |e verfasserin  |4 aut 
700 1 |a Gunnarsson, Iva  |e verfasserin  |4 aut 
700 1 |a Svenungsson, Elisabet  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 212(2020) vom: 15. März, Seite 108349  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:212  |g year:2020  |g day:15  |g month:03  |g pages:108349 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2020.108349  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 212  |j 2020  |b 15  |c 03  |h 108349